Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2025 07:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
March 04, 2025 06:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
March 03, 2025 07:30 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
February 20, 2025 16:05 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
February 06, 2025 07:30 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
January 31, 2025 07:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
January 10, 2025 09:26 ET | Source: Y-mAbs Therapeutics, Inc.

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
January 10, 2025 07:35 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
January 10, 2025 07:05 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
December 23, 2024 07:30 ET | Source: Y-mAbs Therapeutics, Inc.

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...